| Small Lymphocytic Lymphoma
Jaypirca vs Copiktra
Side-by-side clinical, coverage, and cost comparison for small lymphocytic lymphoma.Deep comparison between: Jaypirca vs Copiktra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCopiktra has a higher rate of injection site reactions vs Jaypirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Copiktra but not Jaypirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jaypirca
Copiktra
At A Glance
Oral
Once daily
BTK inhibitor
Oral
Twice daily
PI3K-delta/gamma inhibitor
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Dosing
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 25 mg orally twice daily in 28-day cycles; reduce to 15 mg twice daily for toxicity or when co-administered with strong CYP3A4 inhibitors; discontinue if unable to tolerate 15 mg twice daily.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Most common (>=20%) Diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, anemia
Serious Infection, diarrhea or colitis, pneumonia, rash, pneumonitis
Pharmacology
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
Duvelisib is a PI3K-delta/gamma inhibitor that blocks B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells, inducing growth inhibition and reduced viability in CLL tumor cells and malignant B-cell lines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Copiktra
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Copiktra
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Copiktra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Secura Care Co-Pay Program: CopiktraCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JaypircaView full Jaypirca profile
CopiktraView full Copiktra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.